ASTX727 for acute myeloid leukaemia

ASTX727 is in clinical development for patients with de novo or secondary acute myeloid leukaemia (AML), who are not candidates for standard induction chemotherapy. De novo AML is where there has been no past medical history of the condition or exposure to the drugs which commonly treat it, secondary AML is where patients have had previous conditions that have then developed into AML. AML is a rare form of blood cancer that affects the white blood cells resulting in frequent infections for patients. AML also affects red blood cells resulting in other symptoms such as bleeding and breathlessness. AML is an acute cancer which means it progresses quickly and aggressively, needing immediate treatment. Over half of AML patients are not eligible for intensive chemotherapy due to age or other factors that may make the treatments too dangerous, leaving them with limited treatment options.